- Design
- Systematic review and random-effects meta-analysis of randomised controlled trials
- Population
- Adults with type 2 diabetes; 6 trials (n = 472) for hsCRP, 5 trials (n = 475) for TNF-alpha
- Primary outcome
- Circulating inflammatory biomarkers (hsCRP, TNF-alpha)
- Effect
- hsCRP MD −1.06 mg/L (95% CI −1.97 to −0.16), I² = 17.3%; TNF-alpha g −1.20 (−1.98 to −0.42), I² = 84.9%
This systematic review and meta-analysis pooled randomised trials of oral curcumin or curcuminoids in adults with type 2 diabetes. Six trials (472 participants) contributed hsCRP data and five (475) contributed TNF-alpha.
Curcumin was associated with lower hsCRP (mean difference −1.06 mg/L, 95% CI −1.97 to −0.16, I² = 17.3%). TNF-alpha also fell (Hedges' g −1.20, 95% CI −1.98 to −0.42) but heterogeneity was high (I² = 84.9%). Interleukin-6 and interleukin-1 beta data were too sparse to pool meaningfully. Sensitivity analyses using ambiguous or reconstructed data widened the uncertainty.
Many patients in India already take turmeric or curcumin products. This gives a factual answer when they ask: a small fall in an inflammation marker, from small trials, with no evidence on glucose control, complications or cardiovascular events.
- Ask patients with type 2 diabetes whether they take turmeric or curcumin supplements, and record it with other medicines.
- The evidence is for a modest fall in a blood marker, not for better glucose control or fewer complications.
- A supplement should never replace or delay prescribed glucose-lowering or cardiovascular treatment.
- Supplement products vary widely in curcumin content and absorption.
Why it matters
Patients already use turmeric; this puts a real, and modest, number on what it does.
The statistics, in plain English
The hsCRP confidence interval (−1.97 to −0.16) does not cross zero, so the fall is unlikely to be chance, but its lower end is very small. An I² of 85% for TNF-alpha means the trials disagreed a great deal, so the pooled number is not a reliable single estimate. Six trials with 472 people is a small base for any firm conclusion.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free